Emily Lee

Cooley advised Egnyte, a provider of secure content collaboration and governance solutions, on its strategic growth investment from GI Partners and TA Associates.

Cooley represented Clay, a company that helps go-to-market teams up-level their data enrichment and automate personalized outreach, in its $40 million preemptive Series B expansion funding at a $1.25 billion valuation.

Cooley advised Arsenal Biosciences (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors, on the close of its oversubscribed $325 million Series C financing round.

Cooley advised Clay, a company that helps go-to-market teams up-level their data enrichment and automate personalized outreach, on its $62 million Series B financing, valuing Clay at $500 million.

Cooley advised Cytek Biosciences on its $200 million initial public offering of 14,564,635 shares of common stock. Cytek Biosciences, whose securities now trade on the Nasdaq Global Select Market under the symbol CTKB, is a leading cell analysis solutions company. Partners Gordon Ho, Patrick Loofbourrow and John McKenna led the Cooley team.